MATK

Summary

MATK (megakaryocyte-associated tyrosine kinase, HGNC:6906) is a protein-coding gene on chromosome 19p13.3, encoding Megakaryocyte-associated tyrosine-protein kinase (P42679). Could play a significant role in the signal transduction of hematopoietic cells.

The protein encoded by this gene has amino acid sequence similarity to Csk tyrosine kinase and has the structural features of the CSK subfamily: SRC homology SH2 and SH3 domains, a catalytic domain, a unique N terminus, lack of myristylation signals, lack of a negative regulatory phosphorylation site, and lack of an autophosphorylation site. This protein is thought to play a significant role in the signal transduction of hematopoietic cells. It is able to phosphorylate and inactivate Src family kinases, and may play an inhibitory role in the control of T-cell proliferation. This protein might be involved in signaling in some cases of breast cancer. Three alternatively spliced transcript variants that encode different isoforms have been described for this gene.

Source: NCBI Gene 4145 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 75 total
• GTEx eGene: eQTL in 26 tissues, sQTL in 7 (q < 0.05)
• ChEMBL bioactivity: 10 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.92 (unconstrained)
• MANE Select transcript: NM_139355
• Notable: 75 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6906
Approved symbol	MATK
Name	megakaryocyte-associated tyrosine kinase
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	HYLTK, CTK, HYL, Lsk, CHK, HHYLTK, DKFZp434N1212, MGC1708, MGC2101
Ensembl gene	ENSG00000007264
Ensembl biotype	protein_coding
OMIM	600038
Entrez	4145

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 26 protein_coding, 4 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

MANE Select: ENST00000310132

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2, TSL 3: 3, TSL 4: 6, TSL 5: 1

ENST00000310132, ENST00000395040, ENST00000395045, ENST00000585778, ENST00000587180, ENST00000588983, ENST00000590028, ENST00000590493, ENST00000590821, ENST00000590849, ENST00000590980, ENST00000591059, ENST00000592300, ENST00000592612, ENST00000619596, ENST00000874393, ENST00000874394, ENST00000874395, ENST00000874396, ENST00000874397, ENST00000874398, ENST00000923599, ENST00000923600, ENST00000923601, ENST00000923602, ENST00000923603, ENST00000923604, ENST00001004463, ENST00001029939, ENST00001079958, ENST00001079959, ENST00001079960, ENST00001135118

RefSeq mRNA: 6 — MANE Select: NM_139355 NM_001440577, NM_001440578, NM_001440579, NM_002378, NM_139354, NM_139355

CCDS: CCDS12113, CCDS12114, CCDS42468

Canonical transcript exons

ENST00000310132 — 14 exons

Exon	Start	End
ENSE00000664298	3783814	3784033
ENSE00000875993	3784338	3784451
ENSE00000875996	3783126	3783219
ENSE00000875997	3781607	3781672
ENSE00000875998	3779698	3779797
ENSE00000875999	3779533	3779617
ENSE00000876002	3779378	3779451
ENSE00000876003	3778992	3779187
ENSE00000951594	3778509	3778595
ENSE00002307506	3785064	3785286
ENSE00002770053	3786169	3786381
ENSE00002801673	3777973	3778422
ENSE00003480927	3784825	3784884
ENSE00003690443	3784124	3784239

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 97.80.

FANTOM5 (CAGE): breadth broad, TPM avg 7.6433 / max 313.2340, expressed in 754 samples.

Highest expression (Bgee): granulocyte, cingulate cortex, anterior cingulate cortex, frontal lobe, amygdala.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MATK is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 26 tissues and its splicing (sQTL) in 7 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 33 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Nerve Tibial	eqtl	3.6e-31	+0.85	19:3812468:C:G
Esophagus Mucosa	eqtl	1.9e-25	+1.79	19:3785265:C:T
Cells Cultured fibroblasts	eqtl	4.5e-12	+1.06	19:3786599:C:T
Esophagus Muscularis	eqtl	2.2e-11	+0.58	19:3812468:C:G
Stomach	eqtl	1.1e-09	+0.46	19:3812468:C:G
Artery Aorta	eqtl	1.4e-09	+0.51	19:3812468:C:G
Adipose Visceral Omentum	eqtl	2.2e-09	+0.51	19:3812468:C:G
Lung	eqtl	1.9e-08	+0.45	19:3812468:C:G
Brain Cortex	sqtl	4.6e-08	+1.29	19:3778221:C:T
Thyroid	eqtl	2.3e-07	+0.42	19:3812091:A:G
Brain Caudate basal ganglia	sqtl	1.6e-06	+1.42	19:3793151:G:A
Skin Not Sun Exposed Suprapubic	eqtl	1.9e-06	+0.49	19:3801558:A:C
Esophagus Gastroesophageal Junction	eqtl	1.9e-06	+0.59	19:3812468:C:G
Prostate	eqtl	6.0e-06	+0.50	19:3812468:C:G
Spleen	eqtl	7.9e-05	+0.36	19:3812468:C:G
Whole Blood	eqtl	1.1e-04	+0.11	19:3812468:C:G
Skin Sun Exposed Lower leg	eqtl	1.3e-04	+0.44	19:3801558:A:C
Cells EBV-transformed lymphocytes	eqtl	3.7e-04	+0.43	19:3812468:C:G
Colon Transverse	eqtl	4.1e-04	+0.28	19:3812468:C:G
Spleen	sqtl	1.7e-03	-2.50	19:4250502:C:T

FANTOM5 promoters

5 alternative TSS:

Promoter ID	TPM avg	Samples expressed
178338	4.5685	603
178339	1.7027	502
178337	0.9624	149
178336	0.2563	90
178340	0.1534	61

Top tissues by expression

showing 100 of 280 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	97.80	gold quality
cingulate cortex	UBERON:0003027	93.64	gold quality
anterior cingulate cortex	UBERON:0009835	93.58	gold quality
right frontal lobe	UBERON:0002810	93.18	gold quality
amygdala	UBERON:0001876	91.67	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.67	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.67	gold quality
prefrontal cortex	UBERON:0000451	91.51	gold quality
nucleus accumbens	UBERON:0001882	90.65	gold quality
frontal cortex	UBERON:0001870	89.76	gold quality
putamen	UBERON:0001874	89.72	gold quality
neocortex	UBERON:0001950	89.70	gold quality
caudate nucleus	UBERON:0001873	89.49	gold quality
cerebral cortex	UBERON:0000956	88.88	gold quality
telencephalon	UBERON:0001893	88.65	gold quality
Ammon’s horn	UBERON:0001954	88.16	gold quality
cervix squamous epithelium	UBERON:0006922	87.25	gold quality
temporal lobe	UBERON:0001871	87.22	gold quality
blood	UBERON:0000178	87.15	gold quality
forebrain	UBERON:0001890	86.39	gold quality
Brodmann (1909) area 10	UBERON:0013541	86.28	gold quality
primary visual cortex	UBERON:0002436	86.09	gold quality
occipital lobe	UBERON:0002021	84.67	gold quality
superior frontal gyrus	UBERON:0002661	84.53	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.18	gold quality
brain	UBERON:0000955	83.41	gold quality
Brodmann (1909) area 46	UBERON:0006483	83.32	gold quality
central nervous system	UBERON:0001017	83.11	gold quality
postcentral gyrus	UBERON:0002581	83.05	gold quality
parietal lobe	UBERON:0001872	82.79	gold quality
hypothalamus	UBERON:0001898	82.63	gold quality
spleen	UBERON:0002106	81.81	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	81.47	gold quality
amniotic fluid	UBERON:0000173	81.02	gold quality
middle temporal gyrus	UBERON:0002771	80.98	gold quality
entorhinal cortex	UBERON:0002728	80.93	gold quality
pons	UBERON:0000988	80.25	gold quality
cerebellar vermis	UBERON:0004720	80.18	gold quality
cortical plate	UBERON:0005343	79.72	gold quality
right uterine tube	UBERON:0001302	79.46	gold quality
frontal pole	UBERON:0002795	79.12	gold quality
right lung	UBERON:0002167	79.10	gold quality
endometrium epithelium	UBERON:0004811	78.83	gold quality
periodontal ligament	UBERON:0008266	78.64	gold quality
bone marrow	UBERON:0002371	78.45	gold quality
substantia nigra	UBERON:0002038	78.43	gold quality
lower esophagus mucosa	UBERON:0035834	78.30	gold quality
midbrain	UBERON:0001891	78.17	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.94	gold quality
type B pancreatic cell	CL:0000169	77.91	gold quality
upper lobe of left lung	UBERON:0008952	77.84	gold quality
mucosa of transverse colon	UBERON:0004991	77.81	gold quality
olfactory bulb	UBERON:0002264	77.72	gold quality
lymph node	UBERON:0000029	77.64	gold quality
substantia nigra pars compacta	UBERON:0001965	77.04	gold quality
upper lobe of lung	UBERON:0008948	76.88	gold quality
bone element	UBERON:0001474	76.76	gold quality
Brodmann (1909) area 23	UBERON:0013554	76.73	gold quality
tendon of biceps brachii	UBERON:0008188	76.69	gold quality
upper arm skin	UBERON:0004263	76.68	gold quality
triceps brachii	UBERON:0001509	76.64	gold quality
lateral globus pallidus	UBERON:0002476	76.49	gold quality
secondary oocyte	CL:0000655	76.36	silver quality
oocyte	CL:0000023	76.32	gold quality
orbitofrontal cortex	UBERON:0004167	75.92	gold quality
gluteal muscle	UBERON:0002000	75.87	gold quality
ventral tegmental area	UBERON:0002691	75.72	silver quality
vena cava	UBERON:0004087	75.37	gold quality
tongue squamous epithelium	UBERON:0006919	75.37	gold quality
substantia nigra pars reticulata	UBERON:0001966	75.29	silver quality
middle frontal gyrus	UBERON:0002702	75.09	silver quality
inferior vagus X ganglion	UBERON:0005363	74.75	silver quality
subthalamic nucleus	UBERON:0001906	74.61	silver quality
thymus	UBERON:0002370	74.59	silver quality
dorsal plus ventral thalamus	UBERON:0001897	74.57	silver quality
body of tongue	UBERON:0011876	74.54	silver quality
paraflocculus	UBERON:0005351	74.49	gold quality
cardia of stomach	UBERON:0001162	74.29	silver quality
medulla oblongata	UBERON:0001896	74.17	silver quality
superior vestibular nucleus	UBERON:0007227	74.09	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	74.04	gold quality
pericardium	UBERON:0002407	73.91	silver quality
caecum	UBERON:0001153	73.87	gold quality
spinal cord	UBERON:0002240	73.86	gold quality
decidua	UBERON:0002450	73.85	silver quality
parotid gland	UBERON:0001831	73.80	gold quality
saphenous vein	UBERON:0007318	73.75	silver quality
diaphragm	UBERON:0001103	73.64	gold quality
trabecular bone tissue	UBERON:0002483	73.63	silver quality
gall bladder	UBERON:0002110	73.59	gold quality
duodenum	UBERON:0002114	73.56	gold quality
lateral nuclear group of thalamus	UBERON:0002736	73.52	silver quality
vastus lateralis	UBERON:0001379	73.50	gold quality
pylorus	UBERON:0001166	73.41	gold quality
globus pallidus	UBERON:0001875	73.38	silver quality
nipple	UBERON:0002030	73.37	silver quality
nasal cavity epithelium	UBERON:0005384	73.06	gold quality
vermiform appendix	UBERON:0001154	73.03	gold quality
gingival epithelium	UBERON:0001949	72.91	gold quality
medial globus pallidus	UBERON:0002477	72.78	silver quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-CURD-84	yes	493.58
E-HCAD-4	yes	112.88
E-HCAD-1	yes	82.35
E-CURD-122	yes	51.77
E-MTAB-6701	yes	35.33
E-MTAB-9467	yes	30.55
E-MTAB-10287	yes	29.07
E-HCAD-10	yes	28.68
E-CURD-88	yes	20.11
E-CURD-46	yes	18.42
E-HCAD-9	yes	18.42
E-MTAB-8410	yes	14.26
E-MTAB-10553	yes	12.44
E-CURD-112	yes	11.09
E-MTAB-9067	yes	9.88

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Frontal cortex	tissue	98.9
Caudate putamen	tissue	88.5
Postcentral gyrus	tissue	78.0
Hippocampus	tissue	52.5	not detected
Nucleus accumbens	tissue	27.5
Bone marrow	tissue	19.3	medium
Prefrontal cortex	tissue	19.0
Cerebral cortex	tissue	19.0	low
Motor cortex	tissue	18.7
Hippocampal formation	tissue	18.4
Retrosplenial and cingulate cortex	tissue	18.1
Entorhinal cortex	tissue	16.6
Retrosplenial cortex	tissue	16.5
Somatosensory cortex	tissue	16.2
Insular cortex	tissue	15.8
Locus coeruleus	tissue	15.4
Temporal cortex	tissue	15.3
Amygdala	tissue	13.4
Spleen	tissue	13.4	medium
Occipital cortex	tissue	13.4
Hypothalamus	tissue	11.4
Periaqueductal gray	tissue	9.0
Lymph node	tissue	8.8	medium
Septum	tissue	8.6
Pons	tissue	8.3
Superior colliculi	tissue	8.2
Thalamus	tissue	7.0
Choroid plexus	tissue	6.9
Midbrain	tissue	6.8
Cerebellum	tissue	6.8	not detected
Duodenum	tissue	6.2	low
Appendix	tissue	6.2	medium
Small intestine	tissue	5.8	low
Lung	tissue	5.7	medium
Ventral forebrain	tissue	5.6
Medulla oblongata	tissue	5.5
Substantia nigra	tissue	4.9
Gallbladder	tissue	4.1	low
Olfactory bulb	tissue	4.1
Spinal cord	tissue	4.0
Basal ganglia	tissue	3.9	low
Stomach 1	tissue	3.7	medium
Tonsil	tissue	3.7	high
Fallopian tube	tissue	3.7	not detected
Putamen	tissue	3.6
Thymus	tissue	3.6
Salivary gland	tissue	3.0	medium
Pituitary gland	tissue	2.4
Corpus callosum	tissue	2.3
Liver	tissue	2.2	not detected
Retina	tissue	2.0
Colon	tissue	1.9	medium
Breast	tissue	1.8	low
Testis	tissue	1.7	medium
Urinary bladder	tissue	1.5	not detected
Skin 1	tissue	1.3	low
Heart muscle	tissue	1.3	low
Adipose tissue	tissue	1.3	low
Adrenal gland	tissue	1.2	low
Vagina	tissue	1.1	not detected

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Precentral gyrus (90.6), Posterior cingulate cortex (67.6), Supplementary motor cortex (64.6), Postcentral gyrus, middle (61.0), Frontal eye field (60.8).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HIF1A

miRNA regulators (miRDB)

Targeting MATK by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

5 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-2861	95.24	65.47	1056
HSA-MIR-4800-3P	88.42	63.07	35
HSA-MIR-4750-5P	80.79	59.79	18

Functional genomics

gnomAD constraint: pLI 2.28e-10, LOEUF 0.921, missense Z 1.44 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000310132 — one region, missense o/e 0.82.

Literature-anchored findings (GeneRIF, showing 14)

• ERBB2 binds to the SH2 domain of CHK and inhibits cell growth in human breast tumor cell lines (PMID:12122014)
• Overexpression of the Csk homologous kinase facilitates phosphorylation of akt/protein kinase b in breast neoplasms (PMID:12429987)
• CHK Leu223 stabilizes the movement of the alphaC-helix of the protein tyrosine kinase (PMID:12782282)
• Loss of CHK expression is associated with human brain tumors (PMID:15329911)
• Nuclear multi-lobulation in late S phase, which is dependent on polymerization and depolymerization of microtubules, may be involved in nuclear Chk-induced inhibition of proliferation. (PMID:15748901)
• striking functional differences between the Csk and Chk SH2 domains and revealed functional similarities between the Chk and Src SH2 domains (PMID:15890649)
• This study describes for the first time the Src-independent actions of CHK and provides novel insights into CHK function in neural cells. (PMID:16168623)
• Matk/CHK is not functionally redundant with Csk, and this tyrosine kinase plays an important role as a regulator of immunologic responses (PMID:16574955)
• Findings indicate that the importance of the N-terminal domain to Chk-induced tyrosine phosphorylation in the nucleus, and implicate that nuclear tyrosine-phosphorylated proteins may contribute to inhibition of cell proliferation. (PMID:16707123)
• Progesterone increases MATK in mast cells and reducs cell proliferation. (PMID:17492661)
• These results reveal a potentially important role for CHK in Src activation and tumorigenicity in colon cancer cells. (PMID:17934522)
• CHK is capable of inhibiting the CXCL12-CXCR4 pathway in neuroblastoma. (PMID:18292939)
• After IGF-I stimulation, CTK is recruited to IGF-IR and its recruitment facilitates CTK’s subsequent association with phospho-SHPS-1. (PMID:21799000)
• CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. (PMID:33767439)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	matk	ENSDARG00000074670
mus_musculus	Matk	ENSMUSG00000004933
rattus_norvegicus	Matk	ENSRNOG00000020431

Paralogs (32): FGR (ENSG00000000938), BTK (ENSG00000010671), FYN (ENSG00000010810), STYK1 (ENSG00000060140), TNK2 (ENSG00000061938), TXK (ENSG00000074966), JAK2 (ENSG00000096968), ABL1 (ENSG00000097007), PTK6 (ENSG00000101213), HCK (ENSG00000101336), BMX (ENSG00000102010), CSK (ENSG00000103653), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), FRK (ENSG00000111816), ITK (ENSG00000113263), ZAP70 (ENSG00000115085), PTK2B (ENSG00000120899), SRMS (ENSG00000125508), TEC (ENSG00000135605), BLK (ENSG00000136573), ABL2 (ENSG00000143322), FER (ENSG00000151422), JAK1 (ENSG00000162434), SYK (ENSG00000165025), PTK2 (ENSG00000169398), TNK1 (ENSG00000174292), YES1 (ENSG00000176105), FES (ENSG00000182511), LCK (ENSG00000182866), SRC (ENSG00000197122), LYN (ENSG00000254087)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:99259) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal hematopoietic system physiology	1
abnormal bone marrow cell morphology/development	1
increased hematopoietic stem cell number	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	P00523	100.0%	Diamond
Pongo abelii	Q5RFL3	99.8%	Diamond
Bos taurus	A0JNB0	99.6%	Diamond
Sus scrofa	A1Y2K1	99.4%	Diamond
Pan troglodytes	P0C0K6	99.3%	Diamond
Felis catus	P14238	98.7%	Diamond
Aotus nancymaae	Q5PXS1	98.4%	Diamond
Xenopus laevis	P13115	97.9%	Diamond
Macaca fascicularis	Q95M30	97.8%	Diamond
Saimiri sciureus	Q95KR7	96.9%	Diamond
Canis lupus familiaris	Q9TTY2	95.6%	Diamond
Xiphophorus hellerii	P27446	94.4%	Diamond
Avian sarcoma virus PR2257	P15054	100.0%	Diamond
Avian sarcoma virus S2	P14085	99.8%	Diamond
Avian sarcoma virus S1	P14084	99.6%	Diamond
Gardner-Arnstein feline sarcoma virus	P00542	99.1%	Diamond
Snyder-Theilen feline sarcoma virus	P00543	99.1%	Diamond
Rous sarcoma virus (strain Schmidt-Ruppin A)	P00524	99.0%	Diamond
Avian sarcoma virus RASV1441	P00525	99.0%	Diamond
Rous sarcoma virus - Prague C	P00526	99.0%	Diamond
Rous sarcoma virus (strain H-19)	P25020	99.0%	Diamond
Rous sarcoma virus (strain Schmidt-Ruppin E)	P63185	99.0%	Diamond
Y73 sarcoma virus	P00527	98.9%	Diamond
Rous sarcoma virus (strain PA101T)	P31693	95.6%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ZFR2	protein-coding	23217
NMRK2	protein-coding	27231
ATCAY	protein-coding	85300
TJP3	protein-coding	27134
RAX2	protein-coding	84839
APBA3	protein-coding	9546
MRPL54	protein-coding	116541
PIP5K1C	protein-coding	23396

Protein

Protein identifiers

Megakaryocyte-associated tyrosine-protein kinase — P42679 (reviewed: P42679)

Alternative names: CSK homologous kinase, Hematopoietic consensus tyrosine-lacking kinase, Protein kinase HYL, Tyrosine-protein kinase CTK

All UniProt accessions (10): P42679, F1T0G6, K7EKC4, K7EKS5, K7ENL8, K7EPP2, K7EQV3, K7EQY5, K7ERY4, K7ES68

UniProt curated annotations — full annotation on UniProt →

Function. Could play a significant role in the signal transduction of hematopoietic cells. May regulate tyrosine kinase activity of SRC-family members in brain by specifically phosphorylating their C-terminal regulatory tyrosine residue which acts as a negative regulatory site. It may play an inhibitory role in the control of T-cell proliferation.

Subunit / interactions. Interacts with KIT.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Expressed in various myeloid cell lines, detected in brain and lung.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family. CSK subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
P42679-1	1	yes
P42679-2	2
P42679-3	3

RefSeq proteins (6): NP_001427506, NP_001427507, NP_001427508, NP_002369, NP_647611, NP_647612* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR000980	SH2	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR001452	SH3_domain	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR035027	Csk-like_SH2	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR050198	Non-receptor_tyrosine_kinases	Family

Pfam: PF00017, PF00018, PF07714

Enzyme classification (BRENDA)

• EC 2.7.10.2 — non-specific protein-tyrosine kinase (BRENDA: 41 organisms, 396 substrates, 479 inhibitors, 43 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.014–17.64	12
[KDSRC KINASE]-L-TYROSINE	0.0057–0.24	12
POLY(GLU4-TYR)	0.018–0.659	10
EEEEYIQ[DP]-8-HYDROXY-5-(N,N-DIMETHYLSULFONAMIDO	0.057	1
S1 PEPTIDE	0.037	1
EEEEY	—	0

Catalyzed reactions (Rhea)

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (35 total): strand 13, domain 3, sequence variant 3, sequence conflict 3, helix 3, splice variant 2, binding site 2, chain 1, turn 1, region of interest 1, compositionally biased region 1, active site 1, modified residue 1

Structure

Experimental structures (PDB)

3 structures by resolution:

PDB	Title	Method	Resolution (Å)
3US4	Crystal structure of a SH2 domain of a megakaryocyte-associated tyrosine kinase (MATK) …	X-RAY DIFFRACTION	1.5
1JWO	Crystal Structure Analysis of the SH2 Domain of the Csk Homologous Kinase CHK	X-RAY DIFFRACTION	2.5
1X6G	Solution structures of the SH3 domain of human megakaryocyte-associated tyrosine-protein …	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P42679-F1	84.24	0.63

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Kinases, Tyr protein kinases, Predicted intracellular proteins, Cancer-related genes, Mutational cancer driver genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): microtubules; centriolar satellite; cytokinetic bridge; cytosol; mitotic spindle

Antibody reliability (HPA): IH approved · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
352	proton acceptor

Ligand- & substrate-binding residues (2)

Position	Role
241–249	ATP
262	ATP

Post-translational modifications (1)

Type	Positions
Phosphoserine	501

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

4 pathways:

ID	Pathway	Evidence
R-HSA-8863795	Downregulation of ERBB2 signaling	curated
R-HSA-162582	Signal Transduction	—
R-HSA-1227986	Signaling by ERBB2	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—

MSigDB gene sets: 212 (showing top): RORA1_01, RIZKI_TUMOR_INVASIVENESS_3D_DN, GNF2_ZAP70, MUELLER_PLURINET, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, AMIT_EGF_RESPONSE_120_HELA, GNF2_IL2RB, ZHU_CMV_ALL_DN, ALCALA_APOPTOSIS, GNF2_PTPN4, GAVIN_FOXP3_TARGETS_CLUSTER_P3, BLALOCK_ALZHEIMERS_DISEASE_DN, chr19p13, GOMF_PROTEIN_KINASE_ACTIVITY, RUTELLA_RESPONSE_TO_HGF_UP

GO Biological Process (2): protein phosphorylation (GO:0006468), positive regulation of cell population proliferation (GO:0008284)

GO Molecular Function (8): protein tyrosine kinase activity (GO:0004713), non-membrane spanning protein tyrosine kinase activity (GO:0004715), ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (4): cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Signaling by ERBB2	1
Signaling by Receptor Tyrosine Kinases	1
Signal Transduction	1

GO top-level categories

23 GO namespaces:

Category	Terms
cellular anatomical structure	3
phosphorylation	1
protein modification process	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
protein kinase activity	1
protein tyrosine kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 14 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
cytosol	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 1,354 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MATK	SLAMF1	Q13291	880
MATK	CD48	P09326	799
MATK	PSMA7	O14818	773
MATK	PTPRC	P08575	742
MATK	CD34	P28906	741
MATK	RPS16	P17008	731
MATK	RPL32	P02433	725
MATK	MPP3	Q13368	716
MATK	ABCG1	P45844	707
MATK	ITGAM	P11215	675
MATK	CLPP	Q16740	661
MATK	IL7R	P16871	648
MATK	APOA1	P02647	632
MATK	ITGA2B	P08514	622
MATK	KITLG	P21583	622

IntAct

Human interaction partners of MATK in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

17 partners by confidence:

Partner	Interaction type	MIscore	Records
LRRK2	direct interaction	0.620	2
ERBB2	direct interaction	0.590	2
BACE2	physical association	0.560	3
KLK6	physical association	0.560	3
CSK	association	0.530	2
HSP90AB1	physical association	0.520	2
FRS3	physical association	0.490	2
PTK2B	association	0.460	2
AR	direct interaction	0.440	4
LRRK1	direct interaction	0.440	1
MET	direct interaction	0.440	1
YWHAE	physical association	0.400	2
CDC37	physical association	0.400	1
NOC3L	physical association	0.400	1
SFN	physical association	0.400	1
CACNA1A	physical association	0.370	1
EWSR1	physical association	0.370	1

BioGRID (47 interactions; top human partners by supporting records): SIRPA (Two-hybrid; 11 records), ERBB2 (Affinity Capture-Western; 3 records), CSK (Affinity Capture-MS; 2 records), KIT (Reconstituted Complex; 2 records), NTRK1 (Affinity Capture-Western; 2 records), AKT1 (Reconstituted Complex), AR (Reconstituted Complex), BRCA1 (Affinity Capture-Western), CACNA1A (Two-hybrid), CD36 (Affinity Capture-Western), CUL3 (Affinity Capture-MS), EGFR (Affinity Capture-Western), ERBB3 (Reconstituted Complex), ERBB4 (Reconstituted Complex), EWSR1 (Two-hybrid)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
MATK	“down-regulates activity”	LYN	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 17 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
intracellular signal transduction	5	11.2×	7e-03

Disease & clinical

Genetic variants

Variant evidence for MATK: 75 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	6
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 19 predictions of 1,036):

Position(s)	Effect	Δscore	Sites
19:3778990–3778991	donor_loss	1.0000	6
19:3779188	acceptor_loss	1.0000
19:3779194	acceptor_gain	1.0000
19:3779377	donor_loss	1.0000
19:3779696	donor_loss	1.0000
19:3779805	acceptor_gain	1.0000
19:3783854	donor_gain	1.0000
19:3784034–3784035	acceptor_loss	1.0000	5
19:3784122	donor_loss	1.0000
19:3784137	donor_gain	1.0000

AlphaMissense

1,264 missense substitutions predicted likely pathogenic (of 3,271 scored), across 299 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M340	9	0.947	0.995
N357	8	0.997	0.999
D370	8	0.997	0.999
D406	8	0.996	0.998
D352	8	0.995	0.999
H350	8	0.991	0.998
F371	8	0.982	0.995
H168	8	0.972	0.997
F471	8	0.972	0.996
D155	8	0.958	0.989
F273	8	0.955	0.994
F246	8	0.944	0.999
S409	8	0.943	0.998
F186	8	0.924	0.992
H124	8	0.921	0.994
D267	8	0.913	0.971
H285	8	0.907	0.970
F144	7	0.997	0.999
W390	7	0.997	1.000
F123	7	0.995	0.999

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Breast Invasive Carcinoma (TCGA)	favorable	0.000381
Ovary Serous Cystadenocarcinoma (TCGA)	unfavorable	0.000575

Disease associations

OMIM: gene MIM:600038 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST001762_327	Obesity-related traits	3e-8

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0005109	energy expenditure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4175 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 99,779 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

10 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL288441	BOSUTINIB	4	12,869
CHEMBL1287853	FEDRATINIB	4	3,770
CHEMBL535	SUNITINIB	4	80,232
CHEMBL603469	LESTAURTINIB	3
CHEMBL1967878	CENISERTIB	2	373
CHEMBL1980297	ILORASERTIB	2	613
CHEMBL1721885	SU-014813	2	375
CHEMBL574738	AST-487	1	468
CHEMBL1908397	KW-2449	1	655
CHEMBL1084546	PF-00562271	1	424

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Csk family

Binding affinities (BindingDB)

21 measured of 81 human assays (82 total across all organisms); most potent 21 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	KD	0.37 nM
CEP-701	KD	3.4 nM
4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	IC50	5.5 nM
3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	IC50	5.6 nM	US-8822500: Tyrosine kinase inhibitors
Staurosporine, 8	IC50	6.5 nM
N-[4-[[(2-hydroxy-1H-indol-3-yl)-phenylmethylidene]amino]phenyl]-N-methyl-2-(4-methylpiperazin-1-yl)acetamide	KI	15 nM	US-10981896: Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CHEMBL1240703	KD	15 nM
2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide	IC50	17 nM
PKC-412	KD	110 nM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	KD	120 nM	US-9145414: 1,2,4-triazine-6-carboxamide derivative
CHEMBL1908397	KD	650 nM
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide	KD	740 nM
(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione	IC50	743 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
CHEMBL4090364	IC50	1800 nM
3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol	KD	2400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide	KD	2900 nM
SUNITINIB MALATE	KD	3500 nM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide	KD	3900 nM	US-20250129067: PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF
(4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-yl]amine	KD	8800 nM

ChEMBL bioactivities

61 potent at pChembl≥5 of 62 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.40	Ki	39.81	nM	ILORASERTIB
7.30	Ki	50.12	nM	CHEMBL1993661
7.20	Ki	63.1	nM	CENISERTIB
7.10	Ki	79.43	nM	CHEMBL1978448
7.10	Ki	79.43	nM	CHEMBL1991395
7.00	Ki	100	nM	PF-00562271
6.90	Ki	125.9	nM	CHEMBL1978099
6.80	Ki	158.5	nM	CHEMBL1998585
6.80	Ki	158.5	nM	CHEMBL1988838
6.70	Ki	199.5	nM	CHEMBL1973540
6.60	Ki	251.2	nM	CHEMBL2004716
6.58	Kd	260	nM	STAUROSPORINE
6.50	Ki	316.2	nM	CHEMBL1987034
6.50	Ki	316.2	nM	CHEMBL1989708
6.50	Ki	316.2	nM	CHEMBL422897
6.41	IC50	392	nM	STAUROSPORINE
6.40	Ki	398.1	nM	CHEMBL539474
6.40	Ki	398.1	nM	CHEMBL1964692
6.40	Ki	398.1	nM	CHEMBL243088
6.31	IC50	492	nM	STAUROSPORINE
6.30	Ki	501.2	nM	CHEMBL244378
6.30	Ki	501.2	nM	SP-600125
6.20	Ki	631	nM	CHEMBL1988594
6.20	Ki	631	nM	CHEMBL271381
6.20	Ki	631	nM	CHEMBL1983111
6.10	Ki	794.3	nM	CHEMBL1969372
6.10	Ki	794.3	nM	CHEMBL1985092
6.10	Ki	794.3	nM	CHEMBL196363
6.01	Kd	970	nM	LESTAURTINIB
6.00	Ki	1000	nM	CHEMBL2005886
6.00	Ki	1000	nM	CHEMBL1980896
6.00	Ki	1000	nM	CHEMBL2004544
6.00	Ki	1000	nM	CHEMBL1984162
6.00	Ki	1000	nM	CHEMBL17370
5.90	Ki	1259	nM	CHEMBL1970104
5.89	IC50	1300	nM	STAUROSPORINE
5.89	Kd	1300	nM	AST-487
5.80	Ki	1585	nM	CHEMBL246970
5.80	Ki	1585	nM	CHEMBL1991674
5.80	Ki	1585	nM	CHEMBL1966143
5.80	Ki	1585	nM	CHEMBL1991429
5.80	Ki	1585	nM	CHEMBL508928
5.80	Ki	1585	nM	CHEMBL1990885
5.80	Ki	1585	nM	CHEMBL1965507
5.80	Ki	1585	nM	CHEMBL1979883
5.80	Ki	1585	nM	CHEMBL404367
5.77	Kd	1700	nM	FEDRATINIB
5.70	Ki	1995	nM	CHEMBL1983449
5.70	Ki	1995	nM	CHEMBL1968103
5.70	Ki	1995	nM	CHEMBL2006715

PubChem BioAssay actives

13 with measured affinity, of 682 total; 9 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	624864: Binding constant for CTK kinase domain	kd	0.2600	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507891: Binding affinity to CTK	kd	0.9700	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	624864: Binding constant for CTK kinase domain	kd	1.3000	uM
Fedratinib	624864: Binding constant for CTK kinase domain	kd	1.7000	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624864: Binding constant for CTK kinase domain	kd	2.8000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624864: Binding constant for CTK kinase domain	kd	3.0000	uM
Bosutinib	624864: Binding constant for CTK kinase domain	kd	5.8000	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	624864: Binding constant for CTK kinase domain	kd	6.2000	uM
Sunitinib	624864: Binding constant for CTK kinase domain	kd	7.7000	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression, affects cotreatment	3
Estradiol	increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, increases methylation	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
GW 506033X	increases expression, increases response to substance, decreases reaction	1
triphenyl phosphate	affects expression	1
lead acetate	decreases expression, affects cotreatment	1
ethyl-p-hydroxybenzoate	decreases expression	1
terbufos	increases methylation	1
chromous chloride	affects cotreatment, decreases expression	1
chromic oxide	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenic Trioxide	decreases expression	1
Arsenic	affects expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1
Lead	affects expression	1
Lipopolysaccharides	affects reaction, increases expression, increases response to substance, decreases reaction	1
Parathion	increases methylation	1
Plant Extracts	decreases expression	1
Potassium Dichromate	increases expression	1

ChEMBL screening assays

138 unique, capped per target: 137 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1040684	Binding	Residual activity of MATK at 0.1 uM by microplate scintillation counting	Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization. — *Bioorg Med Chem*
CHEMBL1963689	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MATK	PubChem BioAssay data set

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3AV	Abcam HEK293T MATK KO	Transformed cell line	Female
CVCL_SX34	HAP1 MATK (-) 1	Cancer cell line	Male
CVCL_SX35	HAP1 MATK (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MATK across ~30M SureChEMBL compounds — explore on Sugi Predict.